Enlivex Announces Upcoming May Conference Presentations
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced participation in the Allogeneic Cell Therapies Summit 2022 and the 20th Biomed Israel Conference. Presentations include topics on their innovative therapy, Allocetra™, targeting solid tumors and cytokine storms linked to sepsis and COVID-19. Key details include a presentation on 'Next Generation Allogeneic Modality for Solid Tumors' on May 10, 2022, and two presentations at the Biomed Israel Conference on May 10 and 12. The focus is on the therapeutic potential of Allocetra™ in treating severe conditions.
- Enlivex is set to present at two significant conferences, raising visibility for its lead therapy, Allocetra™.
- Allocetra™ is positioned as a novel immunotherapy targeting unmet medical needs, potentially appealing to investors looking for innovative treatments.
- None.
Nes-Ziona, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will be presenting scientific and clinical overviews in three oral presentations at the Allogeneic Cell Therapies Summit 2022 and the 20th Biomed Israel Conference and Exhibition. Details on the presentations are below.
Allogeneic Cell Therapies Summit 2022
| Conference Location: | DoubleTree by Hilton Boston North Shore (Danvers, MA) |
| Presentation Title: | Next Generation Allogeneic Modality for Solid Tumors: Beyond T-cells or NK cells |
| Presentation Date: | May 10, 2022 |
| Presentation Time: | 5:15 PM ET |
20th Biomed Israel Conference and Exhibition, two presentations
| Conference Location: | David InterContinental (Tel Aviv, Israel) |
| Presentation #1 Title: | In-vivo reprogramming macrophages with Allocetra-OTS: Successful Mono- and in Combination with Immune Check Point Inhibitors-Antitumor Therapy |
| Presentation Track: | Cell, Gene and Nucleic Acids Therapies – The Next Frontier in Human Health |
| Presentation Date: | May 10, 2022 |
| Presentation Time: | 1:45 PM Israel time |
| Presentation #2 Title: | Allocetra-OTS: Reprogramming Macrophages for an Effective Treatment for Cytokine Storms Associated with Sepsis, ARDS and COVID-19 |
| Presentation Track: | Infectious Diseases - Breaking Barriers in Vaccine Development, Therapy and Diagnosis Modalities |
| Presentation Date: | May 12, 2022 |
| Presentation Time: | 12:45 PM Israel time |
ABOUT ALLOCETRATM
Allocetra™ is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra™ has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical needs", as a stand-alone therapy or in combination with leading therapeutic agents.
ABOUT ENLIVEX
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information visit https://enlivex.com/.
Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would", "could," "intends," "estimates," "suggests," "has the potential to" and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex's business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex's filings with the Securities and Exchange Commission, including in the Company's most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com
INVESTOR RELATIONS CONTACT
Eric Ribner
LifeSci Advisors
eric@lifesciadvisors.com
FAQ
What is Enlivex Therapeutics presenting at the Allogeneic Cell Therapies Summit 2022?
When will Enlivex present at the 20th Biomed Israel Conference?
What is Allocetra™ developed by Enlivex Therapeutics?
What are the main topics of Enlivex's presentations at the conferences in May 2022?
